Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice

被引：8
|
作者：
Tang, Lay Hoon [1 ]
Lim, Jie Hui [1 ]
Kuah, Li Fang [1 ]
Lau, Yuk Fai [1 ,2 ]
机构：
[1] DSO Natl Labs, Host Pathogen Interact Lab, DMERI, Singapore 117510, Singapore
[2] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore 169857, Singapore
来源：
VACCINE | 2014年 / 32卷 / 42期
关键词：
Influenza; H7N9; Vaccine; INFLUENZA-A VIRUS; CONVALESCENT PLASMA; PATHOGENICITY; INFECTION;
D O I：
10.1016/j.vaccine.2014.07.087
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A prototype H7 influenza vaccine constructed based on the H7N7 outbreak in 2003 was tested for the protective efficacy against the novel H7N9 virus in a lethal murine challenge model. Serum samples from vaccinated mice showed significant neutralizing activity against the H7N9 virus and the mice were completely protected with no significant weight loss. The results have direct implications on how to overcome potential vaccine shortage and identify donors for immune sera for passive immunization. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5375 / 5378
页数：4
相关论文
共 50 条
  • [1] Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge
    Krammer, Florian
    Albrecht, Randy A.
    Tan, Gene S.
    Margine, Irina
    Hai, Rong
    Schmolke, Mirco
    Runstadler, Jonathan
    Andrews, Sarah F.
    Wilson, Patrick C.
    Cox, Rebecca J.
    Treanor, John J.
    Garcia-Sastre, Adolfo
    Palese, Peter
    JOURNAL OF VIROLOGY, 2014, 88 (08) : 3976 - 3985
  • [2] Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice
    Chang, Haiyan
    Duan, Jie
    Zhou, Peng
    Su, Ling
    Zheng, Dan
    Zhang, Fenghua
    Fang, Fang
    Li, Xiaoman
    Chen, Ze
    MICROBES AND INFECTION, 2017, 19 (12) : 616 - 625
  • [3] Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice
    Han Lei
    Bowen Xie
    Tong Gao
    Qianhong Cen
    Yi Ren
    Microbial Cell Factories, 19
  • [4] Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice
    Lei, Han
    Xie, Bowen
    Gao, Tong
    Cen, Qianhong
    Ren, Yi
    MICROBIAL CELL FACTORIES, 2020, 19 (01)
  • [5] Immunization with a Live Attenuated H7N9 Influenza Vaccine Protects Mice against Lethal Challenge
    Yang, Xiaolan
    Zhao, Jianyu
    Wang, Cheng
    Duan, Yuegiang
    Zhao, Zhongpeng
    Chen, Rui
    Zhang, Liangyan
    Xing, Li
    Lai, Chengcai
    Zhang, Shaogeng
    Wang, Xiliang
    Yang, Penghui
    PLOS ONE, 2015, 10 (04):
  • [6] Antibodies to Antigenic Site A of Influenza H7 Hemagglutinin Provide Protection against H7N9 Challenge
    Schmeisser, Falko
    Vasudevan, Anupama
    Verma, Swati
    Wang, Wei
    Alvarado, Esmeralda
    Weiss, Carol
    Atukorale, Vajini
    Meseda, Clement
    Weir, Jerry P.
    PLOS ONE, 2015, 10 (01):
  • [7] Single Immunization with Newcastle Disease Virus-Vectored H7N9 Vaccine Confers a Complete Protection Against Challenge with Highly Pathogenic Avian Influenza H7N9 Virus
    Shi, Lei
    Hu, Zenglei
    Hu, Jiao
    Liu, Dong
    He, Lihong
    Liu, Jiao
    Gu, Han
    Gan, Junji
    Wang, Xiaoquan
    Liu, Xiufan
    AVIAN DISEASES, 2019, 63 (01) : 61 - 67
  • [8] Tackling a novel lethal virus: a focus on H7N9 vaccine development
    Isakova-Sivak, Irina
    Rudenko, Larisa
    EXPERT REVIEW OF VACCINES, 2017, 16 (07) : 709 - 721
  • [9] Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A( H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus
    Hatta, Masato
    Zhong, Gongxun
    Chiba, Shiho
    Lopes, Tiago J. S.
    Neumann, Gabriele
    Kawaoka, Yoshihiro
    EMERGING INFECTIOUS DISEASES, 2018, 24 (10) : 1910 - 1913
  • [10] A Replication-Defective Influenza Virus Vaccine Confers Complete Protection against H7N9 Viral Infection in Mice
    Landreth, Shelby
    Lu, Yao
    Pandey, Kannupriya
    Zhou, Yan
    VACCINES, 2020, 8 (02)
12345